435 related articles for article (PubMed ID: 29949775)
1. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
2. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
3. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
4. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
[TBL] [Abstract][Full Text] [Related]
6. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
7. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
8. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
10. ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC; Wang X; Wilson BG; Vazquez F; Haswell JR; Manchester HE; Kim Y; Kryukov GV; Ghandi M; Aguirre AJ; Jagani Z; Wang Z; Garraway LA; Hahn WC; Roberts CW
Nat Med; 2014 Mar; 20(3):251-4. PubMed ID: 24562383
[TBL] [Abstract][Full Text] [Related]
11. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
12.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
13. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines.
Kimura A; Arakawa N; Hirano H
J Proteome Res; 2014 Nov; 13(11):4959-69. PubMed ID: 25083560
[TBL] [Abstract][Full Text] [Related]
15. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice.
Mathur R; Alver BH; San Roman AK; Wilson BG; Wang X; Agoston AT; Park PJ; Shivdasani RA; Roberts CW
Nat Genet; 2017 Feb; 49(2):296-302. PubMed ID: 27941798
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
Guan B; Gao M; Wu CH; Wang TL; Shih IeM
Neoplasia; 2012 Oct; 14(10):986-93. PubMed ID: 23097632
[TBL] [Abstract][Full Text] [Related]
18. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
20. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]